Epidemiology of hepatitis C virus infection in Australia

Journal of Clinical Virology

Volumn 26, Issue 2, 2003, Pages 171-184

  Dore, Gregory J ^a   Law, Matthew ^a   MacDonald, Margaret ^a   Kaldor, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Australia; Epidemiology; Hepatitis C virus

Indexed keywords

ARTICLE; AUSTRALIA; BIOAVAILABILITY; COMMUNICABLE DISEASE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG USE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; NEEDLE; PRIORITY JOURNAL; PUBLIC HEALTH; SYRINGE;

ADOLESCENT; ADULT; AGED; AUSTRALIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DISEASE NOTIFICATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POPULATION SURVEILLANCE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0037322668     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(02)00116-6     Document Type: Article

References (69)

1. Alter H.J., Purcell R.H., Shih J.W., Melpolder J.C., Houghton M., Choo Q.L., et al. Detection of antibody to HCV in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321:1989;1494-1500.
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:1999a;556-562.
3. Alter M.J. Hepatitis C virus infection in the United States. J. Hepatol. 31:1999b;88-91.
4. Baker R.I., Smith J., Eikelboom J., Leahy B., Kay I., Lavis N., et al. Hepatitis C genotypes in Australian haemophilia patients. Aust. N.Z. J. Med. 26:1996;789-792.
5. Batey R., Hennessy L., Sievert W. Hepatitis C in non-Australian born populations in Australia, in hepatitis C: informing Australia's National response. 2000;25-46 Commonwealth Department of Health and Aged Care, Publications Production Unit, Commonwealth of Australia, Canberra.
6. Boughton C.R., Hawkes R.A., Schroeter D.R., Ferguson V., Lehmann N.I., Harlor J., et al. Viral hepatitis: a four-year hospital and general-practice study in Sydney 1. Epidemiological features, natural history and laboratory findings. Med. J. Aust. 1:1982;113-119.
7. Brotodihardjo A.E., Tait N., Weltman M.D., Liddle C., Little J.M., Farrell G.C. Hepatocellular carcinoma in western Sydney. Aetiology, changes in incidence, and opportunities for better outcomes. Med. J. Aust. 161:1994;433-435.
8. Butler T.G., Dolan K.A., Ferson M.J., McGuinness L.M., Brown P.R., Robertson P.W. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med. J. Aust. 166:1997;127-130.
9. Chen J.J., McGuinness P.H., Koorey D.J., Rickard K., Wylie B., McCaughan G.W. Hepatitis C virus genotypes in a cohort of Australian blood donors and haemophiliac and liver transplant patients. J. Gastroenterol. Hepatol. 12:1997;182-187.
10. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
11. Copland J. Monitoring newly acquired hepatitis C infection in South Australia. Australian HIV Surveillance Report. National Centre in HIV Epidemiology and Clinical Research 2001;17:1-5.
12. Correll P., MacDonald M., Dore G. Hepatitis C infection in indigenous communities in Australia. In hepatitis C: informing Australia's national response. 2000;47-60 Commonwealth Department of Health and Aged Care, Publications Production Unit, Commonwealth of Australia, Canberra.
13. Cossart Y.E., Kirsch S., Ismay S.L. Post-transfusion hepatitis in Australia. Report of the Australian Red Cross Study. Lancet. 1:1982;208-213.
14. Crofts N., Hopper J.L., Bowden D.S., Breschkin A.M., Milner R., Locarnini S.A. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med. J. Aust. 159:1993;237-241.
15. Crofts N., Stewart T., Hearne P., Xin Y.P., Breschkin A.M., Locarnini S.A. Spread of bloodborne viruses among Australian prison entrants. BMJ. 310:1995;285-288.
16. Crofts N., Jolley D., Kaldor J., van Beek I., Wodak A. Epidemiology of hepatitis C virus infection among injecting drugs users in Australia. J. Epidemiol. Comm. Hlth. 6:1997;692-697.
17. Crofts N., Aitken C.K., Kaldor J.M. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med. J. Aust. 10:1999;220-221.
18. Crofts N. Going where the epidemic is. Epidemiology and control of hepatitis C among injecting drug users. Aust. Fam. Physician. 30:2001;420-425.
19. Day P, Sullivan EA, Lancaster P. Australia's Mothers and Babies 1996, Perinatal Statistics Series. Sydney: Australian Institute of Health and Welfare National Perinatal Statistics Unit; 1999.
20. Dolan K.A. Can hepatitis C transmission be reduced in Australian prisons? Med. J. Aust. 174:2001;378-379.
21. Dore G.J., Kaldor J.M., McCaughan G.W. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ. 315:1997;333-337.
22. Dore G.J., Law M.G., Kaldor J.M. Prevalence of hepatitis C virus infection in the United States. N. Engl. J. Med. 341:1999a;2093-2094.
23. Dore G.J., Pritchard-Jones J., Fisher D., Law M.G. Who's at risk: risk factors for HCV infection in Australia. Aust. Fam. Physician. 28:1999b;8-13.
24. Dore G.J., Freeman A.J., Law M., Kaldor J.M. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastro Hepatol. 17:2002;423-430.
25. Fairley C.K., Leslie D.E., Nicholson S., Gust I.D. Epidemiology an hepatitis C virus in Victoria. Med. J. Aust. 53:1990;271-273.
26. Frank C., Mohamed M.K., Stickland G.T., Lavanchy D., Arthur R.R., Magder L.S., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 355:2000;887-891.
27. Freeman A.J., Zekry A., Whybin L.R., Harvey C.E., van Beek I.A., de Kantzow S.L., et al. Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med. J. Aust. 172:2000;588-591.
28. Freeman A.J., Dore G.J., Law M.G., Thorpe M., Von Overbeck J., Lloyd A.R., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 34:2001;809-816.
29. Garner J.F., Gaughwin M., Dodding J., Willson K. Prevalence of hepatitis C infection in pregnant women in South Australia. Med. J. Aust. 66:1997;470-472.
30. Gust I., Nicholson S., Dimitrakakis M., Hoy J., Lucas R. Prevalence of infection with hepatitis C virus in Australia. Med. J. Aust. 51:1989;719.
31. Hall W.D., Ross J.E., Lynskey M.T., Law M.G., Degenhardt L.J. How many dependent heroin users are there in Australia. Med. J. Aust. 173:2000;528-531.
32. Hyland C.A., Kearns S., Young I.F., Battistutta D., Morgan C.L. Predictive markers for hepatitis C antibody ELISA specificity in Australian blood donors. Transfusion Med. 2:1992;207-213.
33. Ismay S.L., Thomas S., Fellows A., Keller A., Kenrick K.G., Archer G.T., et al. Post-transfusion hepatitis revisited. Med. J. Aust. 163:1995;74-77.
34. Kaba S., Dutta U., Byth K., Crewe E.B., Khan M.H., Coverdale S.A., et al. Molecular epidemiology of hepatitis C in Australia. J. Gastroenterol. Hepatol. 3:1998;914-920.
35. Kaldor J.M., Archer G.T., Buring M.L., Ismay S.L., Kenrick K.G., Lien A.S.M. Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med. J. Aust. 157:1992;227-230.
36. Karim B., Alex G., Smith A.L., Hardikar W. Hepatitis C infection in children: a Melbourne perspective. J. Paediatrics Child Health. 36:2000;385-388.
37. Khan M.H., Farrell G.C., Byth K., Lin R., Weltman M., George J., et al. Which patients with hepatitis C develop liver complications. Hepatology. 31:2000;513-520.
38. Kuo G., Choo Q.L., Alter H.J., Gitnick G.L., Redeker A.G., Purcell A.G., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:1989;362-364.
39. Law M.G. Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group. J. Gastro. Hepatol. 14:1999;1100-1107.
40. Law M.G., Roberts S.K., Dore G.J., Kaldor J.M. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med. J. Aust. 173:1978;403-405.
41. Law M. Estimates and projection of the hepatitis C epidemic in Australia. Proceedings of the third Australasian Conference on Hepatitis C, Melbourne March 2002; 25-27 [abstract 2].
42. Leslie D.E., Rann S., Nicholson S., Fairley C.K., Gust I.D. Prevalence of hepatitis C antibodies in patients with clotting disorders in Victoria. Relationship with other blood borne viruses and liver disease. Med. J. Aust. 156:1992;782-792.
43. McCaw R., Moaven L., Locarnini S.A., Bowden D.S. Hepatitis C virus genotypes in Australia. J. Viral Hepatitis. 4:1997;351-357.
44. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1998;1485-1492.
45. MacDonald M., Crofts N., Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol. Rev. 18:1996;137-148.
46. MacDonald M., Correll P., Dore G. Occupational exposure to hepatitis C in health care settings. In hepatitis C: informing Australia's National response. 2000a;119-135 Commonwealth Department of Health and Aged Care, Publications Production Unit, Commonwealth of Australia, Canberra.
47. MacDonald M.A., Wodak A.D., Dolan K.A., van Beek I., Cunningham P.H., Kaldor J.M. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med. J. Aust. 172:2000b;57-61.
48. Maher L., Sargent P., Higgs P., Crofts N., Kelsall J., Le T.T. Risk behaviours of young Indo-Chinese injecting drug users in Sydney and Melbourne. Aust. N.Z. J. Public Health. 25:2001;50-54.
49. Mison L.M., Young I.F., O'Donoghue M., Cowley N., Thorlton N., Hyland C.A. Prevalence of hepatitis C virus and genotype distribution in an Australian volunteer blood donor population. Transfusion. 37:1997;73-78.
50. Moaven L.D., Crofts N., Locarnini S.A. Hepatitis C virus infection in Victorian injecting drug users in 1971. Med. J. Aust. 158:1993;574.
51. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2001. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW, 2001.
52. Ostapowicz G., Dallinger M., Bell S.J., Strasser S.I., Watson K.J., Slavin J., et al. Changes in hepatitis C-related liver disease in a large clinic population. Intern. Med. J. 31:2001;90-96.
53. Post J.J., Dolan K.A., Whybin L.R., Carter I.W., Haber P.S., Lloyd A.R. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Med. J. Aust. 174:2001;183-184.
54. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
55. Rhodes T., Ball A., Stimson G.V., Kobyshcha Y., Fitch C., Pokrovsky V., et al. HIV infection associated with drug injecting in the newly independent states, Eastern Europe: the social and economic context of epidemics. Addiction. 94:1999;1323-1336.
56. Rooney G., Gilson R.J.C. Sexual transmission of hepatitis C virus infection. Sex Trans. Infect. 74:1998;399-404.
57. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J. The risk of transfusion-transmitted viral infections. The retrovirus epidemiology donor study. N. Engl. J. Med. 334:1996;1685-1690.
58. Selvey L.A., Lush D., Mistry S.A., Sheridan J.W., Krause V., Passaris I., et al. Investigation of notifications of hepatitis C in 1994: the experience of three health departments. Aust. N.Z. J. Public Health. 20:1996;525-529.
59. Seow S.S. Hepatitis in drug dependants. Aust. Fam. Physician. 10:1981;294-298.
60. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. WHO Bull. 77:1999;789-800.
61. Sladden T.J., Hickey A.R., Dunn T.M., Beard J.R. Hepatitis C transmission on the north coast of New South Wales: explaining the unexplained. Med. J. Aust. 166:1997;290-293.
62. Spencer J., Dore G., Robotin M., Correll P., Kaldor J. Outcomes from the first two years of the Australian hepatitis C surveillance strategy. Comm Dis Intell. 26:2002;14-22.
63. Strasser S.I., Watson K.J.R., Lee C.S., Coghlan P.J., Desmond P.V. Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection. Med. J. Aust. 162:1995;355-358.
64. van Beek I., Buckley R., Stewart M., MacDonald M., Kaldor J. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin. Med. 70:1994;321-324.
65. van Beek I., Dwyer R., Dore G.J., Luo K., Kaldor J.M. Infection with HIV and hepatitis C among injecting drug users in a prevention setting: a retrospective cohort study. BMJ. 317:1998;433-437.
66. Wasley A., Alter M. Epidemiology of hepatitis C: geographical differences and temporal trends. Semin. Liver Dis. 20:2000;1-16.
67. WHO Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepatities 1999;6:35-47.
68. Whyte G.S., Savoia H.F. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria. Med. J. Aust. 166:1997;584-586.
69. Williamson G., Wilson J., Low J. Prevalence of infection with hepatitis C in Geelong. Med. J. Aust. 152:1990;504.